GWC leads a £1.5m investment round in Epipole

Greenwood Way Capital is pleased to announce that it has led a £1.5m investment into Epipole with the Scottish Investment Bank also participating.

Epipole’s patented technology enables clinicians to scan the retina using real-time video and then extract high quality images for further examination. Retinal cameras are typically large and costly desktop systems, but Epipole believes it can revolutionise the sector with its portable design and cost-effective pricing.

“We’ve worked with ophthalmologists to test and refine features and capabilities, and will use this funding to implement the key changes needed,” said Dr Craig Robertson, founder and CEO of Epipole. “We will have a particular focus on the US primary care optometry and ophthalmology markets, and plan to have product available by early 2021.”

Ian Stevens has joined as chairman. Stevens is an experienced technology industry executive, holding CEO positions at Scottish businesses Touch Bionics, Mpathy Medical and BioFilm. Previously, he spent nine years at leading retinal imaging company Optos, initially as CFO and then as General Manager of its North American business.

GWC members are excited to be shareholders in such an exciting company that through its success will help reduce blindness in many areas of the world.

GWC introduces early stage companies with disruptive technologies to suitable investors. See www.gwc.london


GWC leads a £1.5m investment round in Epipole

By Greenwood Way Capital01 Jul 2020